Intriguingly, these same conditions may otherwise be detrimental to therapy success as evidenced by reports of folate starvation and consequent MTHFR activity reduction, driving BET inhibitor resistance in AML [19]. The gene discussed is MTHFR; the disease is acute myeloid leukemia.